Three consecutive MM patients with enough bone marrow volume were used for this study. They had plasma cell ratios ranging from 16 to 77% based on morphology and from 4 to 20% based on flow cytometry ( table 1 ). All patients had normal karyotype results by chromosome studies. Interphase MM FISH panel including probe sets of D13S319/13q34, IGH/FGFR3, P53/CEP17 and MLL break apart (Abbott Molecular) revealed only 1-2 anomalies per sample ( table 1 ). After MACs enrichment treatment (Stem Cell Technologies), SNP microarray was performed on both the plasma-enriched and the plasma-depleted fractions, with a total of 2.6 million probes (Affymetrix CytoScan HD array). The microarray result of the plasma-depleted fraction was normal with no pathogenic deletions or duplications; however, microarray results of the plasma-enriched fraction revealed 8-12 chromosomal abnormalities. Follow-up FISH studies confirmed microarray findings using CBFB break apart, LSI 1p36/1q25, BCR, LSI 21 and centromere probes for X, 2, 3, 5, 7, 9, 11, 15, 17, 19 (Abbott Molecular; table 1 ).
Multiple myeloma (MM) is a clonal plasma cell disorder. Chromosome and FISH studies are used to provide prognostic information useful for refining risk stratification and therapeutic response [1] . Frequently, chromosome study is limited by the inability of plasma cells to proliferate in vitro, and FISH is restricted to small probe panels. To alleviate this problem, we have implemented a protocol of magnetic-activated cell sorting (MACs) to isolate abnormal plasma cells followed by high-density single nucleotide polymorphism (SNP) microarray testing to improve our ability to clearly resolve chromosomal copy number abnormalities and to identify loss of heterozygosity (LOH) and copy number-neutral (CNN)-LOH. LOH/CNN-LOH have been shown to be important in cancer biology, where they can lead to tumor suppressor gene inactivation [2] . By applying this methodology, we have been able to increase our diagnostic yield and provide prognostic information on these clonal populations that previously would have been masked by normal cells in patient samples.
Microarrays were also performed on the total cell fraction of specimens from patients 1 and 3, because of their high clonal plasma cell population (77 and 27% by morphology, respectively). By comparing microarray data between the total cell and plasma-enriched fractions of patients 1 and 3 (T and P+ in table 1 , respectively), it is evident that a more refined and accurate profile of chromosome copy number abnormalities is revealed from the plasma-enriched fraction than from the total fraction. For example, for chromosomes 5, 9 and 15 in 235 patient 1, microarray revealed the presence of both trisomies and tetrasomies in the plasma-enriched fraction compared to only trisomies observed in the total cell fraction. Chromosomes 3, 7, 11, 17, 19 and 21 in patient 1 that were clearly trisomies in the plasma-enriched fraction dissolved into partial gain signals in the total cell fraction that were much more difficult to interpret with accuracy. For patient 3, microarray data from the total cell fraction only found the presence of mosaic loss of chromosome 13 and missed eight additional changes, which were revealed by microarray data from the plasma-enriched fraction ( table 1 ) . In all cases, the prognostic information from the microarray of plasma-enriched fractions exceeded that of chromosome and FISH studies combined. According to microarray data, patients 1 and 2 represent hyperdiploidy while patient 3 is an example of hypodiploidy with 1q triplication that is also associated with a poor prognosis [3] . Besides identification of submicroscopic duplications or deletions, SNP microarrays can reveal abnormal allelic imbalances, including LOH and CNN-LOH, which cannot be recognized by chromosome and FISH studies. CNN-LOH is the occurrence of LOH in the absence of allelic loss (copy number ≥ 2) and mosaic CNN-LOH is the mixture of normal and abnormal cells with CNN-LOH ( fig. 1 a) . Mosaic CNN-LOH of 16q was identified in patient 2 ( fig. 1 b) , which has been associated with an adverse prognosis [4] . Patient 3 was found to have complex abnormalities at chromosome 11q, including mosaic deletion at 11q14.1-q22.1, a deletion at 11q22.1-q22.3 and mosaic CNN-LOH at 11q22.3-qter ( fig. 1 c) . Thus, plasma enrichment and SNP microarray provides a clear improvement in the identification of unbalanced chromosome abnormalities, LOH and CNN-LOH.
In summary, SNP microarray testing of MACs-isolated abnormal plasma cells in our MM patients provided a much more comprehensive overview of the genome-wide chromosome copy number abnormalities compared to chromosome and FISH studies. SNP microarray testing is useful in clinical practice to refine our diagnostic and prognostic indicators. This technique can be easily incorporated into clinical cytogenetic laboratory. Although SNP microarray testing cannot reveal any balanced structural abnormalities, such as IGH-FGFR3 fusions, FISH on MACs-isolated abnormal plasma cells will increase the detection rate of clinically relevant genomic abnormalities to overcome the overall low percentage of plasma cells present in primary bone marrow aspirates. Therefore, the combination of SNP microarray results of MACs enriched plasma cells and FISH/chromosome results will present a more complete picture of chromosome abnormalities and provide insights into the mechanisms of MM formation and development. Color version available online
